Why Bruker (BRKR) Shares Are Falling During Thursday's Session
Bruker Corporation BRKR | 0.00 |
Bruker Corp (NASDAQ:BRKR) shares are trading lower by 6.6% to $67.80 during Thursday’s session after the company announced a public offering of 6 million shares of its common stock.
The offering comes with an option for underwriters to purchase an additional 900,000 shares within 30 days. The offering is set to close around May 31, pending customary conditions. The proceeds will be used to reduce debt from recent strategic acquisitions, including repaying part of its revolving credit agreement.
BofA Securities and J.P. Morgan are managing the offering, and the shares will be available on the Nasdaq Global Select Market and other venues at prevailing or negotiated prices.
See Also: US Q1 Economic Growth Downwardly Revised To 1.3%: Consumer Spending Falters
Should I Sell My BRKR Stock?
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Bruker have decreased by 5.73% in the past year. An investor who bought shares of Bruker at the beginning of the year would take a loss of $5.42 per share if they sold it today. The stock has fallen 15.38% over the past month, meaning an investor who bought shares on Apr. 1 would see a capital loss of $24.03.
Bruker shares have an all-time high of $94.27, representing 40.96% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Bruker stock currently has an RSI of 26.13, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
BRKR has a 52-week high of $94.86 and a 52-week low of $53.79.
Recommend
- Benzinga News 19/11 14:02
U.S. Census Bureau To Release August Wholesale Trade Sales And Inventories On Nov. 21; To Release September Advance Monthly Sales For Retail And Food Services On Nov. 25; To Release August Manufacturing And Trade Inventories And Sales On Nov. 25; ...
Benzinga News 19/11 14:24Stock Ratings | With upside potential of 565.02%, Wells Fargo maintains its "Overweight" rating on Annexon (ANNX) and raises its price target from $14 to $27.
Sahm Platform 20/11 06:32Rothschild & Co Initiates Coverage On Bruker with Buy Rating, Announces Price Target of $60
Benzinga News 20/11 12:11This Astera Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Benzinga News 20/11 13:33This Bellring Brands Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Benzinga News 20/11 14:09This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Benzinga News 20/11 17:14Stock Ratings | HC Wainwright & Co. maintained its "buy" rating on Cullinan Therapeutics (CGEM) and raised its price target from $24 to $26, representing a potential upside of 198.17%.
Sahm Platform Today 08:43


